BioLargo (BLGO) 10-Q 16 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 13, 2020
Document Information [Line Items]
Entity Registrant Name	BIOLARGO, INC.
Entity Central Index Key	0000880242
Trading Symbol	blgo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		222,395,857
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 1,117,000	$ 655,000
Accounts receivable, net of allowance	413,000	355,000
Inventories, net of allowance	292,000	16,000
Prepaid expenses and other current assets	51,000	39,000
Total current assets	1,873,000	1,065,000
In-process research and development (Note 8)	2,021,000	1,893,000
Property and equipment, net of depreciation	42,000	95,000
Other non-current assets	823,000	35,000
Right-of-use, operating lease, net of amortization	356,000	411,000
Deferred offering cost		122,000
Investment in South Korean Joint Venture	73,000
Total assets	5,188,000	3,621,000
Current liabilities:
Accounts Payable and Accrued Liabilities, Current, Total	766,000	602,000
Note payable	50,000	50,000
Line of credit	223,000	50,000
Discount on convertible notes payable and line of credit, net of amortization	(149,000)	(1,472,000)
Lease liability	114,000	125,000
Deferred revenue and deposits	72,000	35,000
Total current liabilities	3,189,000	4,354,000
Long-term liabilities:
Long-term debt, noncurrent	507,000	700,000
Discount on convertible notes payable, net of amortization		(182,000)
Lease liability	241,000	286,000
Total liabilities	4,708,000	5,801,000
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit):
Preferred Series A, $.00067 Par Value, 50,000,000 shares authorized, -0- shares issued and outstanding, at December 31, 2019 and September 30, 2020, respectively.
Common stock, $.00067 Par Value, 400,000,000 shares authorized, 166,256,024 and 221,682,140 shares issued, at December 31, 2019 and September 30, 2020, respectively.	148,000	111,000
Additional paid-in capital	135,033,000	121,327,000
Accumulated other comprehensive loss	(107,000)	(99,000)
Accumulated deficit	(130,397,000)	(123,492,000)
Total BioLargo, Inc. and subsidiaries stockholders’ equity (deficit)	4,677,000	(2,153,000)
Non-controlling interest (Note 8)	(4,197,000)	(27,000)
Total stockholders’ equity (deficit)	480,000	(2,180,000)
Total liabilities and stockholders’ equity (deficit)	5,188,000	3,621,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Long-term liabilities:
Liability to Clyra Medical shareholder (Note 8)	771,000	643,000
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Current liabilities:
Note payable	1,007,000	1,007,000
Convertible Notes [Member]
Current liabilities:
Note payable	1,106,000	3,957,000
Convertible Notes and Notes Payable [Member]
Long-term liabilities:
Long-term debt, noncurrent		700,000
Paycheck Protection Program CARES Act and Econonmic Injury Disaster Loans [Member]
Long-term liabilities:
Long-term debt, noncurrent	$ 507,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00067	$ 0.00067
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	221,682,140	166,256,024

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues
Revenue	$ 666,000	$ 534,000	$ 1,522,000	$ 1,324,000
Cost of revenue
Gross profit	365,000	268,000	761,000	638,000
Selling, general and administrative expenses	1,927,000	1,820,000	5,345,000	4,546,000
Research and development	347,000	332,000	1,031,000	1,126,000
Operating loss	(1,909,000)	(1,884,000)	(5,615,000)	(5,034,000)
Other (expense) income:
Interest expense	(318,000)	(1,289,000)	(1,823,000)	(2,773,000)
Loss on debt extinguishment	(228,000)	(801,000)	(442,000)	(1,029,000)
Tax credit	65,000	62,000	109,000	62,000
Grant income		26,000	64,000	149,000
Total other expense:	(481,000)	(2,002,000)	(2,092,000)	(3,591,000)
Net loss	(2,390,000)	(3,886,000)	(7,707,000)	(8,625,000)
Net loss attributable to noncontrolling interest	(284,000)	(207,000)	(901,000)	(572,000)
Net loss attributable to common stockholders	$ (2,106,000)	$ (3,679,000)	$ (6,806,000)	$ (8,053,000)
Net loss per share attributable to common stockholders:
Loss per share attributable to common stockholders – basic and diluted (in dollars per share)	$ (0.01)	$ (0.02)	$ (0.04)	$ (0.06)
Weighted average number of common shares outstanding: (in shares)	210,212,946	156,435,220	182,959,765	148,239,912
Comprehensive loss:
Net loss	$ (2,390,000)	$ (3,886,000)	$ (7,707,000)	$ (8,625,000)
Foreign currency translation	(30,000)	(4,000)	(8,000)	(1,000)
Comprehensive loss	(2,420,000)	(3,890,000)	(7,715,000)	(8,626,000)
Comprehensive loss attributable to noncontrolling interest	(284,000)	(207,000)	(901,000)	(572,000)
Comprehensive loss attributable to common stockholders	(2,136,000)	(3,683,000)	(6,814,000)	(8,054,000)
Product [Member]
Revenues
Revenue	506,000	396,000	1,086,000	1,013,000
Cost of revenue
Cost of Goods and Services Sold	(185,000)	(171,000)	(422,000)	(448,000)
Service [Member]
Revenues
Revenue	160,000	138,000	436,000	311,000
Cost of revenue
Cost of Goods and Services Sold	$ (116,000)	$ (95,000)	$ (339,000)	$ (238,000)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Extension of Convertible Note Maturity Date, Vista Capital [Member]Common Stock [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]Additional Paid-in Capital [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]Retained Earnings [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]AOCI Attributable to Parent [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]Noncontrolling Interest [Member]	Extension of Convertible Note Maturity Date, Vista Capital [Member]	Clyra Medical Technology Inc [Member]Common Stock [Member]	Clyra Medical Technology Inc [Member]Additional Paid-in Capital [Member]	Clyra Medical Technology Inc [Member]Retained Earnings [Member]	Clyra Medical Technology Inc [Member]AOCI Attributable to Parent [Member]	Clyra Medical Technology Inc [Member]Noncontrolling Interest [Member]	Clyra Medical Technology Inc [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2018													141,466,071
Balance at Dec. 31, 2018													$ 95,000	$ 110,222,000	$ (111,723,000)	$ (90,000)	$ 373,000	$ (1,123,000)
Conversion of notes (in shares)													1,638,479
Conversion of notes													$ 1,000	218,000				219,000
Issuance of common stock for service (in shares)													1,229,541
Issuance of common stock for service													$ 1,000	205,000				206,000
Issuance of common stock for interest (in shares)													139,362
Issuance of common stock for interest														25,000				25,000
Stock option compensation expense														352,000				352,000
Warrants and conversion feature issued as discount on convertible notes payable and line of credit														1,115,000				1,115,000
Fair value of warrants for extension of debt		$ 56,000				$ 56,000
Deemed dividend														342,000	(342,000)
Issuance of Clyra Medical common stock														21,000			89,000	110,000
Net loss															(2,576,000)		(173,000)	(2,749,000)
Foreign currency translation																(4,000)		(4,000)
Balance (in shares) at Mar. 31, 2019													144,473,453
Balance at Mar. 31, 2019													$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Balance (in shares) at Dec. 31, 2018													141,466,071
Balance at Dec. 31, 2018													$ 95,000	110,222,000	(111,723,000)	(90,000)	373,000	(1,123,000)
Net loss																		(8,625,000)
Foreign currency translation																		(1,000)
Balance (in shares) at Sep. 30, 2019													158,671,346
Balance at Sep. 30, 2019													$ 106,000	119,421,000	(120,556,000)	(102,000)	110,000	(1,021,000)
Balance (in shares) at Mar. 31, 2019													144,473,453
Balance at Mar. 31, 2019													$ 97,000	112,556,000	(114,641,000)	(94,000)	289,000	(1,793,000)
Conversion of notes (in shares)													2,767,833
Conversion of notes													$ 2,000	294,000				296,000
Issuance of common stock for service (in shares)													981,684
Issuance of common stock for service														213,000				213,000
Issuance of common stock for interest (in shares)													87,478
Issuance of common stock for interest														15,000				15,000
Stock option compensation expense														296,000				296,000
Warrants and conversion feature issued as discount on convertible notes payable and line of credit														756,000				756,000
Deemed dividend														440,000	(440,000)
Issuance of Clyra Medical common stock														74,000			111,000	185,000
Net loss															(1,795,000)		(192,000)	(1,987,000)
Foreign currency translation																(4,000)		(4,000)
Warrant exercise (in shares)													3,744,456
Warrant exercise													$ 3,000	101,000				104,000
Stock issuance to officer (see note 7) (in shares)													500,000
Stock issuance to officer (see note 7)
Balance (in shares) at Jun. 30, 2019													152,554,904
Balance at Jun. 30, 2019													$ 102,000	114,745,000	(116,876,000)	(98,000)	208,000	(1,919,000)
Conversion of notes (in shares)													2,791,300
Conversion of notes													$ 2,000	392,000				394,000
Issuance of common stock for service (in shares)													629,198
Issuance of common stock for service														166,000				166,000
Issuance of common stock for interest (in shares)													395,944
Issuance of common stock for interest														107,000				107,000
Stock option compensation expense														552,000				552,000
Warrants and conversion feature issued as discount on convertible notes payable and line of credit														2,060,000				2,060,000
Issuance of Clyra Medical common stock														66,000			109,000	175,000
Net loss															(3,679,000)		(207,000)	(3,886,000)
Foreign currency translation																(4,000)		(4,000)
Warrant exercise (in shares)													2,300,000
Warrant exercise													$ 2,000	274,000				276,000
Convert BioLargo convertible note to Clyra Medical shares														440,000				440,000
Debt extinguishment expense														619,000				619,000
Balance (in shares) at Sep. 30, 2019													158,671,346
Balance at Sep. 30, 2019													$ 106,000	119,421,000	(120,556,000)	(102,000)	110,000	(1,021,000)
Balance (in shares) at Dec. 31, 2019													166,256,024
Balance at Dec. 31, 2019													$ 111,000	121,327,000	(123,492,000)	(99,000)	(27,000)	(2,180,000)
Conversion of notes (in shares)													3,387,649
Conversion of notes													$ 2,000	432,000				434,000
Issuance of common stock for service (in shares)													1,039,490
Issuance of common stock for service													$ 1,000	177,000				178,000
Issuance of common stock for interest (in shares)													19,278
Issuance of common stock for interest														4,000				4,000
Stock option compensation expense								$ 420,000				$ 420,000		320,000				320,000
Deemed dividend														100,000	(100,000)
Issuance of Clyra Medical common stock														15,000			10,000	25,000
Net loss															(2,274,000)		(342,000)	(2,616,000)
Sale of common stock for cash (in shares)													4,848,305
Sale of common stock for cash													$ 3,000	898,000				901,000
Common stock issued as a financing fee; deferred offering costs (in shares)													2,928,571
Common stock issued as a financing fee; deferred offering costs													$ 2,000	(124,000)				(122,000)
Allocation of noncontrolling interest from Clyra Stock option issuance														(448,000)			448,000
Balance (in shares) at Mar. 31, 2020													178,479,317
Balance at Mar. 31, 2020													$ 119,000	123,121,000	(125,866,000)	(99,000)	89,000	(2,636,000)
Balance (in shares) at Dec. 31, 2019													166,256,024
Balance at Dec. 31, 2019													$ 111,000	121,327,000	(123,492,000)	(99,000)	(27,000)	(2,180,000)
Net loss																		(7,707,000)
Foreign currency translation																		(8,000)
Balance (in shares) at Sep. 30, 2020													221,682,140
Balance at Sep. 30, 2020													$ 148,000	135,033,000	(130,397,000)	(107,000)	(4,197,000)	480,000
Balance (in shares) at Mar. 31, 2020													178,479,317
Balance at Mar. 31, 2020													$ 119,000	123,121,000	(125,866,000)	(99,000)	89,000	(2,636,000)
Conversion of notes (in shares)													6,463,784
Conversion of notes													$ 6,000	682,000				688,000
Issuance of common stock for service (in shares)													1,774,033
Issuance of common stock for service													$ 1,000	271,000				272,000
Issuance of common stock for interest (in shares)													297,001
Issuance of common stock for interest														30,000				30,000
Stock option compensation expense								20,000				$ 20,000		528,000				528,000
Issuance of Clyra Medical common stock														476,000			348,000	824,000
Net loss															(2,425,000)		(275,000)	(2,700,000)
Foreign currency translation																22,000		22,000
Sale of common stock for cash (in shares)												22,513	3,689,246
Sale of common stock for cash													$ 2,000	558,000				560,000
Clyra Medical stock for other asset (See Note 2)														788,000				788,000
Noncontrolling interest allocation														4,401,000			(4,401,000)
Balance (in shares) at Jun. 30, 2020													190,703,381
Balance at Jun. 30, 2020													$ 128,000	130,875,000	(128,291,000)	(77,000)	(4,239,000)	(1,604,000)
Balance (in shares) at Mar. 31, 2020													178,479,317
Balance at Mar. 31, 2020													$ 119,000	123,121,000	(125,866,000)	(99,000)	89,000	(2,636,000)
Balance (in shares) at Sep. 30, 2020													221,682,140
Balance at Sep. 30, 2020													$ 148,000	135,033,000	(130,397,000)	(107,000)	(4,197,000)	480,000
Balance (in shares) at Jun. 30, 2020													190,703,381
Balance at Jun. 30, 2020													$ 128,000	130,875,000	(128,291,000)	(77,000)	(4,239,000)	(1,604,000)
Conversion of notes (in shares)													23,306,528
Conversion of notes													$ 16,000	2,389,000				2,405,000
Issuance of common stock for service (in shares)													619,670
Issuance of common stock for service														93,000				93,000
Issuance of common stock for interest (in shares)													1,412,052
Issuance of common stock for interest													$ 1,000	149,000				150,000
Stock option compensation expense								$ 140,000				$ 140,000		499,000				499,000
Net loss															(2,106,000)		(284,000)	(2,390,000)
Foreign currency translation																(30,000)		(30,000)
Sale of common stock for cash (in shares)													5,640,509
Sale of common stock for cash													$ 3,000	916,000				919,000
Noncontrolling interest allocation														(326,000)			326,000
Loss on extinguishment														228,000				228,000
Clyra Medical shares issued as commitment fee														70,000				70,000
Balance (in shares) at Sep. 30, 2020													221,682,140
Balance at Sep. 30, 2020													$ 148,000	$ 135,033,000	$ (130,397,000)	$ (107,000)	$ (4,197,000)	$ 480,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (7,707,000)	$ (8,625,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1,712,000	1,201,000
Common stock issued in lieu of salary to officers and fees for services from vendors	542,000	587,000
Common stock issued for interest	184,000	147,000
Interest expense related to amortization of the discount on convertible notes payable and line of credit	1,575,000	2,381,000
Interest expense related to the fair value of warrants issued as consent for variable debt		54,000
Loss on extinguishment of debt	442,000	1,029,000
Loss on investment in ODIN	27,000
Deferred offering expense		13,000
Depreciation expense	50,000	48,000
Bad debt expense	11,000
Changes in assets and liabilities:
Accounts receivable	(69,000)	(72,000)
Inventories	(273,000)	7,000
Prepaid expenses and other current assets	(12,000)	(66,000)
Accounts payable and accrued expenses	164,000	88,000
Deferred revenue	37,000
Customer deposits	(1,000)	27,000
Net cash used in operating activities	(3,318,000)	(3,181,000)
Cash flows from investing activities
Investment in South Korean joint venture	(100,000)
Leasehold improvements		(27,000)
Sale of equipment	4,000
Net cash used in investing activities	(96,000)	(27,000)
Cash flows from financing activities
Proceeds from sales of common stock	2,380,000
Proceeds from convertible notes payable		4,335,000
Repayment of note payable	(25,000)	(495,000)
Proceeds from warrant exercise		380,000
Proceeds from SBA program loans	507,000
Proceeds from line of credit Clyra Medical	200,000
Repayment of line of credit Clyra Medical	(27,000)
Net cash provided by financing activities	3,884,000	4,690,000
Net effect of foreign currency translation	(8,000)	(1,000)
Net change in cash	462,000	1,481,000
Cash at beginning of period	655,000	655,000
Cash at end of period	1,117,000	2,136,000
Supplemental disclosures of cash flow information
Interest	81,000	116,000
Income taxes	2,000	3,000
Non-cash investing and financing activities
Fair value of warrants issued with convertible notes		3,931,000
Lincoln Park deferred offering costs, recorded as additional paid-in capital	(122,000)
Deemed dividend	100,000	781,000
Increase in liability to Clyra Medical shareholder	129,000
Fair value of Clyra shares issued as a commitment fee	70,000
Allocation of Clyra stock to noncontrolling interest	4,075,000
Allocation of stock option expense within noncontrolling interest	448,000
Conversion of Convertible Notes Payable into Common Stock [Member]
Non-cash investing and financing activities
Conversion of debt	3,526,000	908,000
Conversion of Convertible Notes Issued with Original Issue Discount [Member]
Non-cash investing and financing activities
Conversion of debt		1,008,000
Exchange of Consulting Services for Shares [Member]
Non-cash investing and financing activities
Exchange of consulting services for Clyra common shares	788,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sales of common stock	$ 849,000	$ 470,000

Note 1 - Business and Organizat

Note 1 - Business and Organization	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air. The company also owns a minority interest in an advanced wound care subsidiary that has licensed BioLargo Technologies and it plans to spin out or sell when the appropriate opportunity is identified. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Liquidity / Going concern For the nine September 30, 2020, $7,707,000, $3,318,000 September 30, 2020, $1,316,000, $1,873,000. not None 10, 2020 3 $1.7 $160,000 no not, no not Organization We are a Delaware corporation formed in 1991. four 2006; No 2009; 2019, 2014; 2016. 97.5% 9 2017. 47% 2012, 2, 8 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, not three nine September 30, 2020, not may December 31, 2020, 10 December 31, 2019 March 31, 2020.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. In the opinion of management, the accompanying balance sheet and related statements of operations, cash flows, and stockholders' deficit include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Principles of Consolidation The consolidated financial statements include the accounts of the Company, and its wholly- and partially-owned subsidiaries, including Clyra Medical. Management believes Clyra Medical's financial statements are appropriately consolidated with that of the Company after reviewing the guidance of ASC Topic 810 , not 47% 8. All intercompany accounts and transactions have been eliminated. Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of December 31, 2019 $24,000 September 30, 2020 $35,000. Credit Concentration We have a limited number of customers that account for significant portions of our revenue. For the nine September 30, 2019 2020, two 10% September 30 , 2019 September 30 , 2020 Customer A <10 % 12 % Customer B 13 % <10 % Customer C 10 % <10 % We had two 10% December 31, 2019 three 10% September 30, 2020, December 31, 2019 September 30 , 2020 Customer A <20 % 15 % Customer D <10 % 15 % Customer E <10 % 10 % Customer F 14 % <10 % Customer G 13 % <10 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2019 September 30, 2020 $3,000 December 31, 2019, September 30, 2020, December 31, 2019 September 30 , 2020 Raw material $ 11 $ 180 Finished goods 5 112 Total $ 16 $ 292 Other Non-Current Assets Other non-current assets consisted of (i) security deposits of $35,000 $787,500 8 Leases In February 2016, No. 2016 02, January 1, 2019 $399,000 may 842, No September 30, 2020, $356,000. Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not September 30, 2019 2020, no 8 Equity Method of Accounting On March 20, 2020, $100,000 40% 30% $150,000 We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not nine September 30, 2020, 40% $27,000. Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2019 2020, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee's performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three nine September 30, 2019 2020: 2019 2020 Non Plan 2018 Plan Non Plan 20 18 Plan Risk free interest rate 2.00 – 2.65% 2.0 – 2.65% 0.66 – 1.02% 0.64 – 1.90% Expected volatility 147 – 152% 147 – 152% 129 – 131% 126 – 133% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not zero Warrants Warrants issued with our convertible promissory notes, note payables, and lines of credit, are accounted for under the fair value and relative fair value method. The warrant is first not. not not The convertible note issued with the warrant is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: We have revenue from four BLEST identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. BLEST's contracts typically call for invoicing for time and materials incurred for that contract. A few contracts have called for milestone or fixed cost payments, where BLEST invoices an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no In the event that we generate revenues from royalties or license fees from our intellectual property, we anticipate a licensee would pay a license fee in one Government Grants We have been awarded multiple research grants from governmental and quasi-governmental institutions. The grants received are considered “other income” and are included in our Consolidated Statements of Operations. We received our first 2015 80 $3.7 third third nine eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may no three September 30, 2020. Not no Fair Value of Financial Instruments Management believes the carrying amounts of the Company's financial instruments (excluding debt and equity instruments) as of December 31, 2019, September 30, 2020,

Note 3 - Equity Financing

Note 3 - Equity Financing	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 3. Lincoln Park During the three March 31, 2020, August 2017 1,398,223 $295,000 14,420 not three nine September 30, 2019. March 2020 August 2017 $122,000 On March 30, , 2020, $10,250,000 three may three 12 no first may not August 2017 1 April 10, 2020. April 21, 2020, April 29, 2020, In the March 30, 2020 2,928,571 $527,000 March 31, 2020. 1,785,715 $250,000. March 31, 2020. Since inception of the March 30, 2020 September 30, 2020, not 6,508,675 $1,043,000. three September 30, 2020, 4,893,981 $797,000. 2020 On May 1, 2020, four five $100,000 $0.25 400,000 four 120% five 150% During the nine September 30, 2020, $367,000 five $0.15 $0.18, 2,318,194 six five 6

Note 4 - Debt Obligations

Note 4 - Debt Obligations	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. The following table summarizes our debt obligations outstanding as of December 31, 2019 September 30, 2020 ( December 31, 2019 September 30 , 2020 C urrent liabilities: Note payable, matures on demand 60 days' notice (or March 8, 2023) $ 50 $ 50 Line of credit, matures September 1, 2019 or later (on 30-day demand) 50 50 Inventory line of credit (Clyra Medical), matures July 6, 2020 (Note 8) — 173 Note payable issued by Clyra Medical to Scion, matures June 17, 2021 (see Note 8) 1,007 1,007 Total notes payable and line of credit $ 1,107 $ 1,280 Convertible notes payable: Convertible note, matured April 7, 2020 270 — Convertible note, matured June 20, 2020 (1) 25 — Convertible 12-month OID notes, mature beginning June 2020 (1) 3,112 — Convertible note payable, matures April 20, 2021 (1) — 100 Convertible note payable, matures August 9, 2021 — 600 Convertible notes, mature August 12 and 16, 2021 550 406 Total convertible notes payable 3,957 1,106 Total current liabilities $ 5,064 $ 2,386 L ong-term liabilities : Convertible note payable, matures August 9, 2021 $ 600 $ — SBA Paycheck Protection Program loans, mature April 2022 — 357 SBA EIDL Loan, matures July 2050 — 150 Convertible notes payable, mature April 20, 2021 (1) 100 — Total long-term liabilities $ 700 $ 507 Total $ 5,764 $ 2,893 ( 1 For the nine September 30, 2019 2020, $2,773,000 $1,823,000 The following discussion includes debt instruments to which amendments were made or included other activity that management deemed appropriate to disclose. Each of the debt instruments contained in the above table are disclosed more fully in the financial statements contained in the Company's Annual Report filed March 31, 2020. SBA Program Loans In April 2020, $218,000, $96,000 $43,000, two 1%. 100% Our subsidiary ONM received an Economic Injury Disaster loan from the U.S. Small Business Administration of $150,000. 30 3.75% $800 July 2021. Convertible Note, matured April 7, 2020 ( On January 7, 2019, $300,000 $330,000. nine one 12%, 65% 25 $300,000, 2019. During the three March 31, 2020, $270,000 2,417,059 Convertible Twelve-month OID notes From June 7, 2019 September 30, 2019, $2,235,000 $2,794,000, 25% 34 $559,000 $2,235,000, twelve During the three September 30, 2019, $305,000 $381,000 25% $76,000 $381,000 twelve Each Twelve-month OID Note is convertible by the investor at any time at $0.17 five 5% $0.17, may 70% 25 nine September 30, 2020, $3,112,000 12 30,208,453 1,415,221 Note Maturity Extensions On August 10, 2020, $475,000 August 12, 2020, August 12, 2021. $0.17 $0.14, September 18, 2023 September 18, 2025, a 1,734,375 August 12, 2024 August 12, 2025 a 2,095,588 $228,000, $119,000 848,214 $24,000 169,643 September 30, 2020 $356,000. On August 10, 2020, $75,000 August 20, 2020, $25,000, August 20, 2021.

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5. Issuance of Common Stock in exchange for payment of payables Payment of Officer Salaries On September 30, 2020, 349,670 $0.15 $52,000 June 30, 2020, 367,403 $0.16 $59,000 March 31, 2020, 648,755 $0.17 $110,000 On September 30, 2019, 35,080 $11,000 $0.31 June 28, 2019, 465,875 $0.23 $107,000 two March 29, 2019, 579,996 $0.16 $93,000 All of these issuances were pursuant to our 2018 Payment of Consultant Fees On September 30, 2020, 270,000 $0.15 $41,000 June 30, 2020, 1,406,630 $0.16 $213,000 March 31, 2020, 390,735 $0.17 $67,000 On September 30, 2019, 594,118 $0.26 $156,000 three June 30, 2019, 515,809 $0.16 $0.23 $107,000 March 29, 2019, 649,545 $0.17 $113,000 Payment of Accrued Interest On September 30, 2020, 1,415,221 $0.11 $150,000 June 30, 2020, 297,001 $0.16 $30,000 March 31, 2020, 19,278 $0.17 $4,000 On September 30, 2019, 87,478 $0.17 $150,000 three June 30, 2019, 87,478 $0.23 $0.43 $15,000 three March 31, 2019, 139,362 $0.17 $0.23 $25,000 Stock Option Expense During the nine September 30, 2019 2020, $1,201,000 $1,347,000, 2018 2007 8 2018 On June 22, 2018, 2018 “2018 may 10 2018 40 2018 January 1 st 2 Activity for our stock options under the 2018 nine September 30, 2019 September 30, 2020, Weighted a verage Aggregate Options Exercise p rice per intrinsic o utstanding p rice per share share v alue (1) Balance, December 31, 2018 1,318,517 $0.22 – 0.43 $ 0.30 Granted 7,072,342 0.16 – 0.40 0.27 Expired — — — Balance, September 30, 2019 8,390,859 $0.16 – 0.43 $ 0.27 Non-vested (4,144,926 ) 0.16 – 0.40 0.29 Vested, September 30, 2019 4,245,933 $0.17 – 0.36 $ 0.23 Balance, December 31, 2019 9,214,356 $0.22 – 0.43 $ 0.25 Granted 9,738,196 0.15 – 0.22 0.15 Expired (1,546,518 ) 0.16 – 0.34 0.26 Balance, September 30, 2020 17,406,034 $0.16 – 0.43 $ 0.20 Non-vested (7,700,981 ) 0.17 – 0.45 0.19 Vested, September 30, 2020 9,705,053 $0.16 – 0.45 $ 0.20 $ 25,000 ( 1 $0.15 September 30, 2020. The options granted under the 2018 9,738,196 nine September 30, 2020 4,880,945 $0.14 19 one $616,000; 517,500 $0.14 $0.21 392,500 nine September 30, 2020, 25,000 January 31, 2021, $100,000; 1,308,934 $0.17 ,$0.16 $0.15 $200,000; 1,346,732 $0.17, $0.16 $0.15 $201,000 four 531,298 $74,000; 1,152,787 $0.14 $0.17 $156,000. 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may 10 September 7, 2017. September 2017, Activity for our stock options under the 2007 nine September 30, 2019 2020 Weighted a verage Aggregate Options Exercise p rice per intrinsic o utstanding p rice per share share v alue (1) Balance, December 31, 2018 9,691,586 $0.23 – 0.94 $ 0.43 Expired (902,135 ) 0.28 – 0.70 0.48 Balance, September 30, 2019 8,789,451 $0.23 – 0.69 $ 0.47 $ — Balance, December 31, 2019 9,691,586 $0.23 – 0.69 $ 0.42 Expired (2,899,425 ) 0.23 – 0.58 0.38 Balance, September 30, 2020 6,792,161 $0.28 – 0.69 $ 0.44 $ — ( 1 $0.15 September 30, 2020. Non-Plan Options issued During the nine September 30, 2020, 820,476 $0.17 $0.21 $135,000, During the nine September 30, 2019, 970,380 $0.16 $0.25 $194,000. nine September 30, 2019 $367,000, Activity of our non-plan stock options issued for the nine September 30, 2019 2020 Weighted Non-plan a verage Aggregate o ptions Exercise p rice per intrinsic As of September 30 , 2019 : o utstanding p rice per share share value (1) Balance, December 31, 2018 19,319,496 $0.23 – 1.00 $ 0.43 Granted 970,380 0.16 – 0.25 0.19 Expired (691,975 ) 0.55 0.55 Balance, September 30, 2019 19,597,901 $0.16 – 1.00 $ 0.42 As of September 30 , 2020 : Balance, December 31, 2019 19,888,718 $0.23 – 1.00 $ 0.41 Granted 820,476 0.15 – 0.21 0.16 Balance, September 30, 2020 20,709,194 $0.15 – 1.00 $ 0.40 Non-vested (2,818,774 ) 0.17 – 0.45 0.45 Vested, September 30, 2020 17,890,420 $0.15 – 1.00 $ 0.39 $ — ( 1 $0.15 September 30, 2020.

Note 6 - Warrants

Note 6 - Warrants	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Warrants [Text Block]	Note 6. We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Weighted a verage Aggregate Warrants Exercise p rice per intrinsic As of September 30 , 2019 : o utstanding p rice per share share value (1) Balance, December 31, 2018 26,872,430 $0.25 – 1.00 $ 0.42 Issued 24,321,947 0.10 – 0.30 0.21 Expired (7,505,746 ) 0.10 – 0.12 0.11 Balance, September 30, 2019 43,688,631 $0.10 – 1.00 $ 0.35 As of September 30 , 2020 : Balance, December 31, 2019 43,231,161 $0.16 – 1.00 $ 0.35 Issued 5,427,648 0.13 – 0.24 0.20 Expired (14,272,820 ) 0.40 – 0.49 0.46 Balance, September 30, 2020 34,385,989 $0.16 – 1.00 $ 0.29 $ 75,000 ( 1 $0.15 September 30, 2020. Warrants issued in private offering During the three September 30, 2020, 2020 3 six 746,528 $0.192 $0.216 five 746,528 $0.24 $0.27 nine September 30, 2020, six 2,318,194 $0.18 $0.22 five 2,318,194 $0.225 $0.27 Fair Value – Interest Expense To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option pricing model and the relative fair values are amortized over the life of the warrant. For the determination of expense of warrants issued for services, extinguishment of debt and settlement management also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: September 30, 2019 September 30, 2020 Risk free interest rate 1.42 – 2.62% 0.15 – 0.23% Expected volatility 86 – 110% 100 – 112 Expected dividend yield — — Forfeiture rate — — Expected life in years 2 – 5 0.33 – 5 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7. Accounts payable and accrued expenses included the following (in thousands): December 31, 2019 September 30 , 2020 Accounts payable and accrued expenses $ 346 $ 475 Accrued interest 123 122 Accrued payroll 133 169 Total accounts payable and accrued expenses $ 602 $ 766 Accounts payable and accrued expenses includes ordinary business payables incurred by the Company and its operational subsidiaries.

Note 8 - Noncontrolling Interes

Note 8 - Noncontrolling Interest - Clyra Medical	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8. We consolidate the operations of our partially owned subsidiary Clyra Medical (see Note 2 Acquisition of In-process Research and Development On September 26, 2018, 21,000 10,000 7,142,858 $1,250,000 $1 On December 17, 2018, $1 one 15,500 one fifth 2,000 1,100 785,714 $100,000 $100,000 $500,000 $1 $2 During the three September 30, 2020, $100,000, first 3,100 $128,000 Scion Solutions – Note Payable and Clyra Liability The promissory note in the principal amount of $1,250,000 September 26, 2018 ( 5%. 25% June 17, 2020, 12 12 25% 12 5% At September 30, 2020, $1,007,000. $771,000 Inventory Line of Credit On June 30, 2020, $1,000,000 first $200,000 July 6, 2020. one $200,000. The line of credit note earns interest at 15%, one first 180 30% 60% 323 $100,000. may Clyra has received a second 12 Clyra Financing During the nine September 30, 2020, 2,742 $310 During June 2020, 23,004 22,513 22,513 2. As of September 30, 2020, no Shareholder Shares Percent BioLargo, Inc. 49,207 47% Sanatio Capital 18,704 18% Scion Solutions ( 1 ) 18,600 17% Other 19,118 18% Total 105,629 (2) Notes: ( 1 not 12,400 ( 2 not 10,153 During 2019, December 31, 2019, 7,624 three nine September 30, 2020, 645 2,685 $1.00 10 three nine September 30, 2020, $140,000 $580,000, $214,000 $310 no 30%. Consulting Agreement Clyra entered into a consulting agreement with Beach House Consulting, LLC, through which Jack B. Strommen will be providing consulting services to Clyra related to its sales and marketing activities, and in exchange receive $23,000 four June 30, 2020, 3,639 $250,000 three 2

Note 9 - BioLargo Engineering,

Note 9 - BioLargo Engineering, Science and Technologies, LLC	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Wholly-Owned Subsidiary [Text Block]	Note 9. In September 2017, three six two 100% no five 30% 1,750,000 five March 31, 2018 ( not 90% 10% first September 2018. Since the commencement of operations, the Compensation Committee has met twice, once in September 2018, November 2019. 2018, not not one In November 2019, one 2.5% not 2.5%

Note 10 - Business Segment Info

Note 10 - Business Segment Information	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 10. BioLargo currently has four four 1. ONM Environmental (formerly Odor- No 2. Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies, including Clyraguard Personal Protective Spray; 3. BLEST -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed (located in Oak Ridge, Tennessee); and 4. BioLargo Water (“Water”) -- which historically focused entirely on R&D, and has now shifted its focus to commercializing the AOS technology, developing manufacturing operations for hand sanitizers and supporting the development of iodine based disinfecting products for the company (located in Edmonton, Alberta Canada). Historically, none third The segment information for the three nine September 30, 2019 2020, Three months ended September 30, Nine months ended September 30, 201 9 20 20 201 9 20 20 Revenue ONM $ 396 $ 356 $ 1,012 $ 952 BLEST 308 334 732 778 Clyra Medical — 124 — 145 Water — 21 — 21 Intercompany revenue (170 ) (169 ) (420 ) (374 ) Total $ 534 $ 666 $ 1,324 $ 1,522 Operating loss BioLargo corporate $ (1,347 ) $ (870 ) $ (3,250 ) $ (2,970 ) ONM (90 ) (144 ) (231 ) (431 ) Clyra Medical (338 ) (491 ) (944 ) (1,219 ) BLEST 27 (298 ) (110 ) (465 ) Water (136 ) (106 ) (499 ) (530 ) Total $ (1,884 ) $ (1,909 ) $ (5,034 ) $ (5,615 ) As of September 30, 2020 BioLargo ONM Clyra BLEST Water Elimination (1) Total Tangible assets $ 867 $ 561 $ 1,332 $ 282 $ 93 $ (41 ) $ 3,094 Investment in South Korean joint venture 73 — — — — — 73 Intangible assets 2,021 — — — — — 2,021 As of December 31, 2019 BioLargo ONM Clyra BLEST Water Elimination (1) Total Tangible assets $ 862 $ 410 $ 3 $ 396 $ 77 $ (31 ) $ 1,728 Intangible assets 1,893 — — — — — 1,893 ( 1

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11. COVID- 19 On March 11, 2020, 2019 19” 19 may may third may 19 may 19 not may Office Leases We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. For the nine September 30, 2019 2020, $156,000 $167,000, January 1, 2019, 842 not not August 2016, August 2020, 3%, four four four four not one September 2022, one five No one None not no 18%. September 30, 2020, three $578,000.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. Management has evaluated subsequent events through the date of the filing of this Quarterly Report and management noted the following for disclosure. Sales of Stock to Lincoln Park From October 1, 2020, November 11, 2020, 943,667 3 $135,000 1, 333 237651. Inventory Line of Credit (Clyra Medical) Subsequent to September 30, 2020, $60,000 8

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company, and its wholly- and partially-owned subsidiaries, including Clyra Medical. Management believes Clyra Medical's financial statements are appropriately consolidated with that of the Company after reviewing the guidance of ASC Topic 810 , not 47% 8. All intercompany accounts and transactions have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of BioLargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not
Receivable [Policy Text Block]	Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts as of December 31, 2019 $24,000 September 30, 2020 $35,000.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We have a limited number of customers that account for significant portions of our revenue. For the nine September 30, 2019 2020, two 10% September 30 , 2019 September 30 , 2020 Customer A <10 % 12 % Customer B 13 % <10 % Customer C 10 % <10 % We had two 10% December 31, 2019 three 10% September 30, 2020, December 31, 2019 September 30 , 2020 Customer A <20 % 15 % Customer D <10 % 15 % Customer E <10 % 10 % Customer F 14 % <10 % Customer G 13 % <10 %
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of December 31, 2019 September 30, 2020 $3,000 December 31, 2019, September 30, 2020, December 31, 2019 September 30 , 2020 Raw material $ 11 $ 180 Finished goods 5 112 Total $ 16 $ 292
Other Assets, Policy [Policy Text Block]	Other Non-Current Assets Other non-current assets consisted of (i) security deposits of $35,000 $787,500 8
Lessee, Leases [Policy Text Block]	Leases In February 2016, No. 2016 02, January 1, 2019 $399,000 may 842, No September 30, 2020, $356,000.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not September 30, 2019 2020, no 8
Equity Method Investments [Policy Text Block]	Equity Method of Accounting On March 20, 2020, $100,000 40% 30% $150,000 We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not nine September 30, 2020, 40% $27,000.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2019 2020,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Share-based Payment Arrangement [Policy Text Block]	Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee's performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the three nine September 30, 2019 2020: 2019 2020 Non Plan 2018 Plan Non Plan 20 18 Plan Risk free interest rate 2.00 – 2.65% 2.0 – 2.65% 0.66 – 1.02% 0.64 – 1.90% Expected volatility 147 – 152% 147 – 152% 129 – 131% 126 – 133% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not zero
Warrant Policy [Policy Text Block]	Warrants Warrants issued with our convertible promissory notes, note payables, and lines of credit, are accounted for under the fair value and relative fair value method. The warrant is first not. not not The convertible note issued with the warrant is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing common stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The BCF value is accounted for as equity. The warrant and BCF relative fair values are also recorded as a discount to the convertible promissory notes.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: We have revenue from four BLEST identifies services to be performed in a written contract, which specifies the performance obligations and the rate at which the services will be billed. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed. BLEST's contracts typically call for invoicing for time and materials incurred for that contract. A few contracts have called for milestone or fixed cost payments, where BLEST invoices an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no In the event that we generate revenues from royalties or license fees from our intellectual property, we anticipate a licensee would pay a license fee in one
Government Grants [Policy Text Block]	Government Grants We have been awarded multiple research grants from governmental and quasi-governmental institutions. The grants received are considered “other income” and are included in our Consolidated Statements of Operations. We received our first 2015 80 $3.7 third third nine eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may no three September 30, 2020. Not no
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Management believes the carrying amounts of the Company's financial instruments (excluding debt and equity instruments) as of December 31, 2019, September 30, 2020,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	September 30 , 2019 September 30 , 2020 Customer A <10 % 12 % Customer B 13 % <10 % Customer C 10 % <10 % December 31, 2019 September 30 , 2020 Customer A <20 % 15 % Customer D <10 % 15 % Customer E <10 % 10 % Customer F 14 % <10 % Customer G 13 % <10 %
Schedule of Inventory, Current [Table Text Block]	December 31, 2019 September 30 , 2020 Raw material $ 11 $ 180 Finished goods 5 112 Total $ 16 $ 292
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2019 2020 Non Plan 2018 Plan Non Plan 20 18 Plan Risk free interest rate 2.00 – 2.65% 2.0 – 2.65% 0.66 – 1.02% 0.64 – 1.90% Expected volatility 147 – 152% 147 – 152% 129 – 131% 126 – 133% Expected dividend yield — — — — Forfeiture rate — — — — Life in years 10 10 10 10

Note 4 - Debt Obligations (Tabl

Note 4 - Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Debt [Table Text Block]	December 31, 2019 September 30 , 2020 C urrent liabilities: Note payable, matures on demand 60 days' notice (or March 8, 2023) $ 50 $ 50 Line of credit, matures September 1, 2019 or later (on 30-day demand) 50 50 Inventory line of credit (Clyra Medical), matures July 6, 2020 (Note 8) — 173 Note payable issued by Clyra Medical to Scion, matures June 17, 2021 (see Note 8) 1,007 1,007 Total notes payable and line of credit $ 1,107 $ 1,280 Convertible notes payable: Convertible note, matured April 7, 2020 270 — Convertible note, matured June 20, 2020 (1) 25 — Convertible 12-month OID notes, mature beginning June 2020 (1) 3,112 — Convertible note payable, matures April 20, 2021 (1) — 100 Convertible note payable, matures August 9, 2021 — 600 Convertible notes, mature August 12 and 16, 2021 550 406 Total convertible notes payable 3,957 1,106 Total current liabilities $ 5,064 $ 2,386 L ong-term liabilities : Convertible note payable, matures August 9, 2021 $ 600 $ — SBA Paycheck Protection Program loans, mature April 2022 — 357 SBA EIDL Loan, matures July 2050 — 150 Convertible notes payable, mature April 20, 2021 (1) 100 — Total long-term liabilities $ 700 $ 507 Total $ 5,764 $ 2,893

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted a verage Aggregate Options Exercise p rice per intrinsic o utstanding p rice per share share v alue (1) Balance, December 31, 2018 1,318,517 $0.22 – 0.43 $ 0.30 Granted 7,072,342 0.16 – 0.40 0.27 Expired — — — Balance, September 30, 2019 8,390,859 $0.16 – 0.43 $ 0.27 Non-vested (4,144,926 ) 0.16 – 0.40 0.29 Vested, September 30, 2019 4,245,933 $0.17 – 0.36 $ 0.23 Balance, December 31, 2019 9,214,356 $0.22 – 0.43 $ 0.25 Granted 9,738,196 0.15 – 0.22 0.15 Expired (1,546,518 ) 0.16 – 0.34 0.26 Balance, September 30, 2020 17,406,034 $0.16 – 0.43 $ 0.20 Non-vested (7,700,981 ) 0.17 – 0.45 0.19 Vested, September 30, 2020 9,705,053 $0.16 – 0.45 $ 0.20 $ 25,000 Weighted Non-plan a verage Aggregate o ptions Exercise p rice per intrinsic As of September 30 , 2019 : o utstanding p rice per share share value (1) Balance, December 31, 2018 19,319,496 $0.23 – 1.00 $ 0.43 Granted 970,380 0.16 – 0.25 0.19 Expired (691,975 ) 0.55 0.55 Balance, September 30, 2019 19,597,901 $0.16 – 1.00 $ 0.42 Balance, December 31, 2019 19,888,718 $0.23 – 1.00 $ 0.41 Granted 820,476 0.15 – 0.21 0.16 Balance, September 30, 2020 20,709,194 $0.15 – 1.00 $ 0.40 Non-vested (2,818,774 ) 0.17 – 0.45 0.45 Vested, September 30, 2020 17,890,420 $0.15 – 1.00 $ 0.39 $ —
The 2007 Equity Incentive Plan [Member]
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted a verage Aggregate Options Exercise p rice per intrinsic o utstanding p rice per share share v alue (1) Balance, December 31, 2018 9,691,586 $0.23 – 0.94 $ 0.43 Expired (902,135 ) 0.28 – 0.70 0.48 Balance, September 30, 2019 8,789,451 $0.23 – 0.69 $ 0.47 $ — Balance, December 31, 2019 9,691,586 $0.23 – 0.69 $ 0.42 Expired (2,899,425 ) 0.23 – 0.58 0.38 Balance, September 30, 2020 6,792,161 $0.28 – 0.69 $ 0.44 $ —

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted a verage Aggregate Warrants Exercise p rice per intrinsic As of September 30 , 2019 : o utstanding p rice per share share value (1) Balance, December 31, 2018 26,872,430 $0.25 – 1.00 $ 0.42 Issued 24,321,947 0.10 – 0.30 0.21 Expired (7,505,746 ) 0.10 – 0.12 0.11 Balance, September 30, 2019 43,688,631 $0.10 – 1.00 $ 0.35 Balance, December 31, 2019 43,231,161 $0.16 – 1.00 $ 0.35 Issued 5,427,648 0.13 – 0.24 0.20 Expired (14,272,820 ) 0.40 – 0.49 0.46 Balance, September 30, 2020 34,385,989 $0.16 – 1.00 $ 0.29 $ 75,000
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	September 30, 2019 September 30, 2020 Risk free interest rate 1.42 – 2.62% 0.15 – 0.23% Expected volatility 86 – 110% 100 – 112 Expected dividend yield — — Forfeiture rate — — Expected life in years 2 – 5 0.33 – 5

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2019 September 30 , 2020 Accounts payable and accrued expenses $ 346 $ 475 Accrued interest 123 122 Accrued payroll 133 169 Total accounts payable and accrued expenses $ 602 $ 766

Note 8 - Noncontrolling Inter_2

Note 8 - Noncontrolling Interest - Clyra Medical (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Shareholder Shares Percent BioLargo, Inc. 49,207 47% Sanatio Capital 18,704 18% Scion Solutions ( 1 ) 18,600 17% Other 19,118 18% Total 105,629 (2)

Note 10 - Business Segment In_2

Note 10 - Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three months ended September 30, Nine months ended September 30, 201 9 20 20 201 9 20 20 Revenue ONM $ 396 $ 356 $ 1,012 $ 952 BLEST 308 334 732 778 Clyra Medical — 124 — 145 Water — 21 — 21 Intercompany revenue (170 ) (169 ) (420 ) (374 ) Total $ 534 $ 666 $ 1,324 $ 1,522 Operating loss BioLargo corporate $ (1,347 ) $ (870 ) $ (3,250 ) $ (2,970 ) ONM (90 ) (144 ) (231 ) (431 ) Clyra Medical (338 ) (491 ) (944 ) (1,219 ) BLEST 27 (298 ) (110 ) (465 ) Water (136 ) (106 ) (499 ) (530 ) Total $ (1,884 ) $ (1,909 ) $ (5,034 ) $ (5,615 ) As of September 30, 2020 BioLargo ONM Clyra BLEST Water Elimination (1) Total Tangible assets $ 867 $ 561 $ 1,332 $ 282 $ 93 $ (41 ) $ 3,094 Investment in South Korean joint venture 73 — — — — — 73 Intangible assets 2,021 — — — — — 2,021 As of December 31, 2019 BioLargo ONM Clyra BLEST Water Elimination (1) Total Tangible assets $ 862 $ 410 $ 3 $ 396 $ 77 $ (31 ) $ 1,728 Intangible assets 1,893 — — — — — 1,893

Note 1 - Business and Organiz_2

Note 1 - Business and Organization (Details Textual)	Mar. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Sep. 30, 2017
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total		$ (2,390,000)	$ (2,700,000)	$ (2,616,000)	$ (3,886,000)	$ (1,987,000)	$ (2,749,000)		$ (7,707,000)	$ (8,625,000)
Net Cash Provided by (Used in) Operating Activities, Total									(3,318,000)	(3,181,000)
Working Capital		(1,316,000)						$ (1,316,000)	(1,316,000)
Assets, Current, Total		$ 1,873,000						$ 1,873,000	1,873,000		$ 1,065,000
Proceeds from Issuance of Common Stock									$ 2,380,000
Number of Wholly-Owned Subsidiaries		4						4	4
BioLargo Engineering, Science & Technologies, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent		97.50%						97.50%	97.50%			100.00%
BioLargo Engineering, Science & Technologies, LLC [Member] | Clyra Medical Technology Inc [Member]
Noncontrolling Interest, Ownership Percentage by Parent		47.00%						47.00%	47.00%
Lincoln Park Capital Fund, LLC [Member]
Proceeds from Issuance of Common Stock	$ 250,000	$ 797,000		$ 295,000				$ 1,043,000	$ 1,700,000
Average Proceeds per Month from Issuance of Common Stock									$ 160,000

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Mar. 20, 2020USD ($)	Jun. 30, 2020	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)
Accounts Receivable, Allowance for Credit Loss, Current			$ 35,000		$ 24,000
Inventory Valuation Reserves, Ending Balance			3,000		3,000
Security Deposit			35,000
Operating Lease, Right-of-Use Asset			356,000		$ 411,000
Impairment of Long-Lived Assets Held-for-use			0	$ 0
Payments to Acquire Interest in Joint Venture			100,000
Income (Loss) from Equity Method Investments, Total			$ (27,000)
Number of Wholly-Owned Subsidiaries			4
Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate		0.00%
Canadian Government Grants [Member]
Number of Grants Received			80
Grants Receivable			$ 3,700,000
Canadian Government Grants [Member] | Minimum [Member]
Grant Term (Month)			270 days
Canadian Government Grants [Member] | Maximum [Member]
Grant Term (Month)			1 year 180 days
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset						$ 399,000
Operating Lease, Liability, Total						$ 399,000
Other Noncurrent Assets [Member]
Prepaid Consulting Fees			$ 787,500
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers				2
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers			3		2
Odin Co Ltd [Member]
Payments to Acquire Interest in Joint Venture	$ 100,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	40.00%		40.00%
Income (Loss) from Equity Method Investments, Total			$ (27,000)
Clyra Medical Technology Inc [Member] | Biolargo [Member]
Noncontrolling Interest, Ownership Percentage by Parent			47.00%
Tomorrow Water [Member] | Odin Co Ltd [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	30.00%
BKT and Tomorrow Water [Member] | Odin Co Ltd [Member]
Payments to Acquire Interest in Joint Venture	$ 150,000
BKT Tech Co Ltd [Member] | Odin Co Ltd [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	30.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer Concentration Risk [Member]	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Customer A [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	12.00%	10.00%
Customer A [Member] | Accounts Receivable [Member]
Credit concentration	15.00%		20.00%
Customer B [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	13.00%
Customer D [Member] | Accounts Receivable [Member]
Credit concentration	15.00%		10.00%
Customer C [Member] | Revenue from Contract with Customer Benchmark [Member]
Credit concentration	10.00%	10.00%
Customer E [Member] | Accounts Receivable [Member]
Credit concentration	10.00%		10.00%
Customer F [Member] | Accounts Receivable [Member]
Credit concentration	10.00%		14.00%
Customer G [Member] | Accounts Receivable [Member]
Credit concentration	10.00%		13.00%

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Raw material	$ 180	$ 11
Finished goods	112	5
Total	$ 292	$ 16

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Non Plan [Member]
Life in years (Year)	10 years	10 years
Non Plan [Member] | Minimum [Member]
Risk free interest rate	0.66%	2.00%
Expected volatility	129.00%	147.00%
Non Plan [Member] | Maximum [Member]
Risk free interest rate	1.02%	2.65%
Expected volatility	131.00%	152.00%
2018 Equity Incentive Plan [Member]
Life in years (Year)	10 years	10 years
2018 Equity Incentive Plan [Member] | Minimum [Member]
Risk free interest rate	0.64%	2.00%
Expected volatility	126.00%	147.00%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Risk free interest rate	1.90%	2.65%
Expected volatility	133.00%	152.00%

Note 3 - Equity Financing (Deta

Note 3 - Equity Financing (Details Textual) - USD ($)	Mar. 30, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	May 01, 2020
Proceeds from Issuance of Common Stock						$ 2,380,000
Stock Issued During Period, Value, Commitment Fee		$ 70,000
Investment from Five Investors [Member]
Stock Issued During Period, Shares, New Issues (in shares)						2,318,194
Proceeds from Issuance of Common Stock						$ 367,000
Investment from Five Investors [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.15			$ 0.15	$ 0.15
Investment from Five Investors [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.18			$ 0.18	$ 0.18
Four Month Warrant [Member]
Warrant Exercise Price, Percent of Unit Price								120.00%
Five Year Warrant [Member]
Warrant Exercise Price, Percent of Unit Price								150.00%
Warrants and Rights Outstanding, Term (Month)		5 years			5 years	5 years
Warrants Issued in Connection with Investment from Five Investors [Member]
Warrants and Rights Outstanding, Term (Month)		180 days			180 days	180 days
Warrants Issued in Connection with Investment from Five Investors [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term (Month)		180 days			180 days	180 days
Warrants Issued in Connection with Investment from Five Investors [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Month)		5 years			5 years	5 years
Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,785,715	4,893,981	1,398,223	0	6,508,675		0
Proceeds from Issuance of Common Stock	$ 250,000	$ 797,000	$ 295,000		$ 1,043,000	$ 1,700,000
Stock Issued During Period, Shares, Additional Commitment (in shares)			14,420
Stock Purchase Agreement, Remaining Offering Costs			$ 122,000
Stock Purchase Agreement, Maximum Amount of Common Stock	$ 10,250,000
Stock Issued During Period, Shares, Commitment Fee (in shares)	2,928,571
Stock Issued During Period, Value, Commitment Fee	$ 527,000

Note 4 - Debt Obligations (Deta

Note 4 - Debt Obligations (Details Textual) - USD ($)	Aug. 10, 2020	Jan. 07, 2019	Apr. 30, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Aug. 09, 2020	Dec. 31, 2019	Dec. 31, 2018
Interest Expense, Debt, Total								$ 1,823,000	$ 2,773,000
Gain (Loss) on Extinguishment of Debt, Total	$ (228,000)			$ (228,000)		$ (801,000)		$ (442,000)	$ (1,029,000)
Class of Warrant or Right, Outstanding (in shares)				34,385,989		43,688,631	43,688,631	34,385,989	43,688,631		43,231,161	26,872,430
Warrant with September 18, 2025 Expiration [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1,734,375
Class of Warrant or Right, Outstanding (in shares)	1
Warrant with August 12, 2025 Expiration [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	2,095,588
Class of Warrant or Right, Outstanding (in shares)	1
Vista Capital Note Converted into Common Stock [Member]
Debt Conversion, Original Debt, Amount					$ 270,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)					2,417,059
Conversion of Convertible Note Into Twelve Month OID Note [Member]
Debt Conversion, Original Debt, Amount						$ 305,000
Conversion of OID Notes to Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.17	$ 0.17		$ 0.17
Conversion of Convertible Notes Payable into Common Stock [Member]
Debt Conversion, Original Debt, Amount								$ 3,112,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)								30,208,453
Conversion of Convertible Notes Payable into Common Stock to Pay for Interest [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)								1,415,221
Conversion from Convertible Promissory Note with August 12, 2021 Maturity to Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 119,000
Debt Conversion, Converted Instrument, Shares Issued (in shares)	848,214
Conversion from Convertible Promissory Note Accrued Interest with August 12, 2021 Maturity to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	169,643
Debt Conversion, Accrued Interest, Amount	$ 24,000
Vista Capital 2019 Note [Member] | Convertible Notes Payable [Member] | Vista Capital [Member]
Debt Instrument, Face Amount		$ 330,000
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Proceeds from Convertible Debt		$ 300,000
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Bid Price		65.00%
Debt Instrument, Convertible, Number of Consecutive Trade Days Prior to Conversion Date (Year)		25 years
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 300,000
Convertible Twelve Months OID Notes [Member]
Debt Instrument, Face Amount						$ 2,794,000	$ 2,794,000		$ 2,794,000
Debt Instrument, Term (Year)							1 year
Debt Instrument, Interest Rate, Stated Percentage						5.00%	5.00%		5.00%
Proceeds from Convertible Debt							$ 2,235,000
Debt Instrument, Convertible, Beneficial Conversion Feature							2,235,000
Debt Instrument, Unamortized Discount, Total						$ 559,000	$ 559,000		$ 559,000
Debt Instrument, Convertible, Conversion Price, Percentage of Lowest Closing Volume Weighted Average Price						70.00%	70.00%		70.00%
Debt Instrument, Convertible, Number of Consecutive Trade Days Preceding The Conversion (Day)						25 days
Convertible Twelve Months OID Notes [Member] | Thirty Four Accredited Investors [Member]
Original Issue Discount, Percentage						25.00%	25.00%		25.00%
Convertible Twelve Months OID Notes [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount						$ 381,000	$ 381,000		$ 381,000
Debt Instrument, Term (Year)						1 year
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 381,000
Original Issue Discount, Percentage						25.00%	25.00%		25.00%
Debt Instrument, Unamortized Discount, Total						$ 76,000	$ 76,000		$ 76,000
Convertible Promissory Note with August 12, 2021 Maturity [Member]
Debt Instrument, Face Amount	$ 475,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.14									$ 0.17
Convertible Debt, Total	$ 356,000
Convertible Promissory Note with August 20, 2021 Maturity [Member]
Debt Instrument, Face Amount	75,000
Debt Instrument, Extension Fee Amount	$ 25,000
ONM [Member] | Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Debt			$ 218,000
BLEST [Member] | Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Debt			96,000
Clyra Medical [Member]
Gain (Loss) on Extinguishment of Debt, Total								$ (214,000)
Clyra Medical [Member] | Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Debt			$ 43,000
Odor-No-More [Member] | Economic Injury Disaster Loan [Member]
Debt Instrument, Face Amount				$ 150,000				$ 150,000
Debt Instrument, Term (Year)								30 years
Debt Instrument, Interest Rate, Stated Percentage				3.75%				3.75%
Debt Instrument, Periodic Payment, Total								$ 800

Note 4 - Debt Obligations - Sch

Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands		Sep. 30, 2020	Dec. 31, 2019
Notes Payable, Current, Total		$ 50	$ 50
Line of credit		223	50
Total notes payable and line of credit		1,280	1,107
Convertible notes		1,106	3,957
Total current liabilities		2,386	5,064
Long-term debt		507	700
Total		2,893	5,764
Note Payable, Maturing March 8, 2023 [Member]
Notes Payable, Current, Total		50	50
Line of Credit, Maturing September 1, 2019 [Member]
Line of credit		50	50
Inventory Line of Credit [Member]
Line of credit		173
Convertible Notes Issued by Clyra Medical Maturing on June 17, 2020 [Member]
Notes Payable, Current, Total		1,007	1,007
Convertible Note, Maturing April 7, 2020 [Member]
Convertible notes			270
Convertible Notes, Maturing on June 20, 2020 [Member]
Convertible notes			25
Long-term debt	[1]		100
Convertible Twelve Months OID Notes [Member]
Convertible notes	[1]		3,112
Convertible Note, Maturing April 20 2021 [Member]
Convertible notes	[1]	100
Convertible Note, Maturing August 9, 2021 [Member]
Convertible notes		600
Long-term debt			600
Convertible Notes, Maturing August 12 and 16, 2020 [Member]
Convertible notes		406	550
Paycheck Protection Program CARES Act [Member]
Long-term debt		357
Economic Injury Disaster Loan [Member]
Long-term debt		$ 150
[1]	These notes are convertible at our option at maturity.

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Jun. 28, 2019	Mar. 31, 2019	Mar. 29, 2019	Jun. 22, 2018	Sep. 07, 2017	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Stock Issued During Period, Value, Issued for Services											$ 93,000	$ 272,000	$ 178,000	$ 166,000	$ 213,000	$ 206,000
Stock Issued During Period, Value, New Issues											919,000	$ 560,000	$ 901,000
Accounts Payable and Accrued Liabilities, Current, Total	$ 766,000										$ 766,000						$ 766,000		$ 602,000
2018 Equity Incentive Plan [Member]
Shares Issued, Price Per Share (in dollars per share)	$ 0.15										$ 0.15						$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)									10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)									40,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares)									2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	9,738,196	7,072,342
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.15	$ 0.27
The 2007 Equity Incentive Plan [Member]
Shares Issued, Price Per Share (in dollars per share)	0.15										0.15						0.15
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
Non Plan [Member]
Shares Issued, Price Per Share (in dollars per share)	0.15										0.15						$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	820,476	970,380
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.16	$ 0.19
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense																	$ 1,347,000	$ 1,201,000
Common Stock Issued for Accrued Interest Due on Promissory Note [Member]
Shares Issued, Price Per Share (in dollars per share)	0.11	$ 0.16	$ 0.17	$ 0.17							0.11	$ 0.16	$ 0.17	$ 0.17			$ 0.11	$ 0.17
Stock Issued During Period, Shares, New Issues (in shares)		297,001	19,278		87,478		139,362										1,415,221	87,478
Stock Issued During Period, Value, New Issues		$ 30,000	$ 4,000		$ 15,000		$ 25,000										$ 150,000	$ 150,000
Minimum [Member] | Common Stock Issued for Accrued Interest Due on Promissory Note [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 0.23		$ 0.17								$ 0.23	$ 0.17
Maximum [Member] | Common Stock Issued for Accrued Interest Due on Promissory Note [Member]
Shares Issued, Price Per Share (in dollars per share)					0.43		$ 0.23								$ 0.43	$ 0.23
Officer [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)		367,403	648,755			465,875		579,996									349,670	35,080
Shares Issued, Price Per Share (in dollars per share)	$ 0.15	$ 0.16	$ 0.17	$ 0.31		$ 0.23		$ 0.16			0.15	0.16	0.17	0.31			$ 0.15	$ 0.31
Stock Issued During Period, Value, Issued for Services	$ 52,000	$ 59,000	$ 110,000	$ 11,000		$ 107,000		$ 93,000
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)		1,406,630	390,735					649,545							515,809		270,000	594,118
Shares Issued, Price Per Share (in dollars per share)	$ 0.15	$ 0.16	$ 0.17	$ 0.26				$ 0.17			$ 0.15	$ 0.16	$ 0.17	$ 0.26			$ 0.15	$ 0.26
Stock Issued During Period, Value, Issued for Services		$ 213,000	$ 67,000	$ 41,000				$ 113,000							$ 107,000			$ 156,000
Accounts Payable and Accrued Liabilities, Current, Total	$ 74,000										$ 74,000						$ 74,000
Consultants [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	531,298
Consultants [Member] | Minimum [Member]
Shares Issued, Price Per Share (in dollars per share)					0.16										$ 0.16
Consultants [Member] | Maximum [Member]
Shares Issued, Price Per Share (in dollars per share)					$ 0.23										$ 0.23
Employees, Consultations, Officers, and Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	9,738,196
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	4,880,945
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.14
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																	1 year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	616,000										616,000						$ 616,000
Chief Executive Officer [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	517,500
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	100,000										100,000						$ 100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)																	392,500
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member] | Vesting Monthly [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options Expected to Vest, Number of Shares (in shares)																	25,000
Chief Financial Officer [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.14
Chief Financial Officer [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.21
Board Of Directors [Member] | Equity Incentive Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	200,000										200,000						$ 200,000
Board Of Directors [Member] | Equity Incentive Plan 2007 [Member] | Award Date One [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.17
Board Of Directors [Member] | Equity Incentive Plan 2007 [Member] | Award Date Two [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	0.16
Board Of Directors [Member] | Equity Incentive Plan 2007 [Member] | Award Date Three [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.15
Board Of Directors [Member] | Minimum [Member] | Equity Incentive Plan 2007 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	1,308,934
Employees [Member] | 2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	1,346,732
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)																	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	201,000										201,000						$ 201,000
Employees [Member] | 2018 Equity Incentive Plan [Member] | Converted Accrued and Unpaid Obligations for Previous Issued Expired Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	1,152,787
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 156,000										$ 156,000						$ 156,000
Employees [Member] | 2018 Equity Incentive Plan [Member] | Award Date One [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.17
Employees [Member] | 2018 Equity Incentive Plan [Member] | Award Date Two [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	0.16
Employees [Member] | 2018 Equity Incentive Plan [Member] | Award Date Three [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	0.15
Employees [Member] | Minimum [Member] | 2018 Equity Incentive Plan [Member] | Converted Accrued and Unpaid Obligations for Previous Issued Expired Options [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	0.14
Employees [Member] | Maximum [Member] | 2018 Equity Incentive Plan [Member] | Converted Accrued and Unpaid Obligations for Previous Issued Expired Options [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)																	$ 0.17
Vendors [Member] | Non Plan [Member]
Share-based Payment Arrangement, Expense																		$ 194,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)																	820,476	970,380
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value				$ 367,000										$ 367,000				$ 367,000
Vendors [Member] | Non Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense																	$ 135,000
Vendors [Member] | Minimum [Member] | Non Plan [Member]
Shares Issued, Price Per Share (in dollars per share)	$ 0.17			$ 0.16							$ 0.17			$ 0.16			$ 0.17	$ 0.16
Vendors [Member] | Maximum [Member] | Non Plan [Member]
Shares Issued, Price Per Share (in dollars per share)	$ 0.21			$ 0.25							$ 0.21			$ 0.25			$ 0.21	$ 0.25

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Options (Details)	9 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares		Sep. 30, 2019USD ($)$ / sharesshares
2018 Equity Incentive Plan [Member]
Options outstanding, balance (in shares) | shares	9,214,356		1,318,517
Weighted average exercise price per share, balance (in dollars per share)	$ 0.25		$ 0.30
Options granted (in shares) | shares	9,738,196		7,072,342
Weighted average exercise price per share, granted (in dollars per share)	$ 0.15		$ 0.27
Options expired (in shares) | shares	(1,546,518)
Weighted average exercise price per share, Expired (in dollars per share)	$ 0.26
Options Non-vested (in shares) | shares	(7,700,981)		(4,144,926)
Weighted average exercise price per share, Non-vested (in dollars per share)	$ 0.19		$ 0.29
Options Vested (in shares) | shares	9,705,053		4,245,933
Weighted average exercise price per share, Vested (in dollars per share)	$ 0.20		$ 0.23
Vested, aggregate intrinsic value | $	$ 25,000	[1]
Options outstanding, balance (in shares) | shares	17,406,034		8,390,859
Weighted average exercise price per share, balance (in dollars per share)	$ 0.20		$ 0.27
2018 Equity Incentive Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)	0.22		0.22
Exercise price per share, granted (in dollars per share)	0.15		0.16
Exercise price per share, Expired (in dollars per share)	0.16
Exercise price per share, Non-vested (in dollars per share)	0.17		0.16
Exercise price per share, Vested (in dollars per share)	0.16		0.17
Exercise price per share, balance (in dollars per share)	0.16		0.16
2018 Equity Incentive Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)	0.43		0.43
Exercise price per share, granted (in dollars per share)	0.22		0.40
Exercise price per share, Expired (in dollars per share)	0.34
Exercise price per share, Non-vested (in dollars per share)	0.45		0.40
Exercise price per share, Vested (in dollars per share)	0.45		0.36
Exercise price per share, balance (in dollars per share)	$ 0.43		$ 0.43
Non Plan [Member]
Options outstanding, balance (in shares) | shares	19,888,718		19,319,496
Weighted average exercise price per share, balance (in dollars per share)	$ 0.41		$ 0.43
Options granted (in shares) | shares	820,476		970,380
Weighted average exercise price per share, granted (in dollars per share)	$ 0.16		$ 0.19
Options expired (in shares) | shares			(691,975)
Exercise price per share, Expired (in dollars per share)			$ 0.55
Weighted average exercise price per share, Expired (in dollars per share)			$ 0.55
Options Non-vested (in shares) | shares	(2,818,774)
Weighted average exercise price per share, Non-vested (in dollars per share)	$ 0.45
Options Vested (in shares) | shares	17,890,420
Weighted average exercise price per share, Vested (in dollars per share)	$ 0.39
Options outstanding, balance (in shares) | shares	20,709,194		19,597,901
Weighted average exercise price per share, balance (in dollars per share)	$ 0.40		$ 0.42
Non Plan [Member] | Minimum [Member]
Exercise price per share, balance (in dollars per share)	0.23		0.23
Exercise price per share, granted (in dollars per share)	0.15		0.16
Exercise price per share, Non-vested (in dollars per share)	0.17
Exercise price per share, Vested (in dollars per share)	0.15
Exercise price per share, balance (in dollars per share)	0.15		0.16
Non Plan [Member] | Maximum [Member]
Exercise price per share, balance (in dollars per share)	1		1
Exercise price per share, granted (in dollars per share)	0.21		0.25
Exercise price per share, Non-vested (in dollars per share)	0.45
Exercise price per share, Vested (in dollars per share)	1
Exercise price per share, balance (in dollars per share)	$ 1		$ 1
[1]	Aggregate intrinsic value based on closing common stock price of $0.15 at September 30, 2020.

Note 5 - Share-based Compensa_5

Note 5 - Share-based Compensation - Stock Options Issued Under the 2007 Equity Incentive Plan (Details) - The 2007 Equity Incentive Plan [Member] - $ / shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Options outstanding, balance (in shares)	9,691,586	9,691,586
Options expired (in shares)	(2,899,425)	(902,135)
Options outstanding, balance (in shares)	6,792,161	8,789,451
Minimum [Member]
Exercise price per share, balance (in dollars per share)	$ 0.23	$ 0.23
Exercise price per share, Expired (in dollars per share)	0.23	0.28
Exercise price per share, balance (in dollars per share)	0.28	0.23
Maximum [Member]
Exercise price per share, balance (in dollars per share)	0.69	0.94
Exercise price per share, Expired (in dollars per share)	0.58	0.70
Exercise price per share, balance (in dollars per share)	0.69	0.69
Weighted Average [Member]
Weighted average exercise price per share, balance (in dollars per share)	0.42	0.43
Weighted average exercise price per share, Expired (in dollars per share)	0.38	0.48
Weighted average exercise price per share, balance (in dollars per share)	$ 0.44	$ 0.47

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2020$ / sharesshares	Sep. 30, 2020$ / sharesshares
Share Price (in dollars per share)	$ 0.15	$ 0.15
Warrants Issued in Connection with Investment from Five Investors [Member]
Warrants and Rights Outstanding, Term (Month)	180 days	180 days
Class of Warrant or Right, Issued During Period, Number of Securities Called by Warrants or Rights (in shares) | shares	746,528	2,318,194
Warrants Issued in Connection with Investment from Five Investors [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term (Month)	180 days	180 days
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)		$ 0.18
Warrants Issued in Connection with Investment from Five Investors [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Month)	5 years	5 years
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)		$ 0.22
Warrants Issued During Three Months Ended in Connection with Investment from Five Investors [Member] | Minimum [Member]
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)	$ 0.192
Warrants Issued During Three Months Ended in Connection with Investment from Five Investors [Member] | Maximum [Member]
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)	$ 0.216
Five Year Warrant [Member]
Warrants and Rights Outstanding, Term (Month)	5 years	5 years
Class of Warrant or Right, Issued During Period, Number of Securities Called by Warrants or Rights (in shares) | shares	746,528
Five Year Warrant [Member] | Minimum [Member]
Class of Warrant or Right, Issued During Period, Number of Securities Called by Warrants or Rights (in shares) | shares		2,318,194
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)	$ 0.24	$ 0.225
Five Year Warrant [Member] | Maximum [Member]
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)	$ 0.27	$ 0.27

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - USD ($)		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Balance, outstanding (in shares)		43,231,161	26,872,430
Issued (in shares)		5,427,648	24,321,947
Expired (in shares)		(14,272,820)	(7,505,746)
Balance, outstanding (in shares)		34,385,989	43,688,631
Balance, aggregate intrinsic value	[1]	$ 75,000
Minimum [Member]
Balance, outstanding, price range (in dollars per share)		$ 0.16	$ 0.25
Issued, price range (in dollars per share)		0.13	0.10
Expired, price range (in dollars per share)		0.40	0.10
Balance, outstanding, price range (in dollars per share)		0.16	0.10
Maximum [Member]
Balance, outstanding, price range (in dollars per share)		1	1
Issued, price range (in dollars per share)		0.24	0.30
Expired, price range (in dollars per share)		0.49	0.12
Balance, outstanding, price range (in dollars per share)		1	1
Weighted Average [Member]
Balance, outstanding, price range (in dollars per share)		0.35	0.42
Issued, price range (in dollars per share)		0.20	0.21
Expired, price range (in dollars per share)		0.46	0.11
Balance, outstanding, price range (in dollars per share)		$ 0.29	$ 0.35
[1]	Aggregate intrinsic value based on closing common stock price of $0.15 at September 30, 2020.

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Minimum [Member]
Risk free interest rate	0.15%	1.42%
Expected volatility	100.00%	86.00%
Expected life (Year)	120 days	2 years
Maximum [Member]
Risk free interest rate	0.23%	2.62%
Expected volatility	112.00%	110.00%
Expected life (Year)	5 years	5 years

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts payable and accrued expenses	$ 475	$ 346
Accrued interest	122	123
Accrued payroll	169	133
Total accounts payable and accrued expenses	$ 766	$ 602

Note 8 - Noncontrolling Inter_3

Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual) - USD ($)	Aug. 10, 2020	Jul. 06, 2020	Jun. 30, 2020	Dec. 17, 2018	Sep. 26, 2018	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Notes Payable, Current, Total						$ 50,000			$ 50,000		$ 50,000
Stock Issued During Period, Value, Commitment Fee						70,000
Gain (Loss) on Extinguishment of Debt, Total	$ (228,000)					$ (228,000)		$ (801,000)	$ (442,000)	$ (1,029,000)
Share Price (in dollars per share)						$ 0.15			$ 0.15
Clyra Medical Technology Inc [Member]
Stock Issued During Period, Shares, New Issues (in shares)							22,513
Noncontrolling Interest, Increased Investment, Shares (in shares)							23,004
Clyra Medical [Member]
Revenues, Total						$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)									2,742
Shares Issued, Price Per Share (in dollars per share)						$ 310			$ 310
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						10,153			10,153		7,624
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						645			2,685
Gain (Loss) on Extinguishment of Debt, Total									$ (214,000)
Share Price (in dollars per share)						$ 310			$ 310
Clyra Medical [Member] | Beach House Consulting, LLC [Member]
Consulting Services, Monthly Payment									$ 23,000
Consulting Services, Period of Services (Year)									4 years
Stock Issued During Period, Shares, Issued for Services (in shares)			3,639
Consulting Services, Three Consecutive Month Average Revenue Threshold for Consulting Fees to Accrue									$ 250,000
Clyra Medical [Member] | Vendors and Employees [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)									$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)									10 years
Clyra Medical [Member] | Vendors and Employees [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense						$ 140,000			$ 580,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate									30.00%
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member]
Debt Instrument, Interest Rate, Stated Percentage			15.00%				15.00%
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,000,000				$ 1,000,000
Proceeds from Lines of Credit, Total		$ 200,000
Line of Credit Facility, Covenant, Additional Draws, Maximum Percentage of Total Principal Outstanding Allowed			50.00%				50.00%
Line of Credit Facility, Covenant, Additional Draws, Minimum Amount Allowed			$ 200,000				$ 200,000
Debt Instrument, Term (Year)			1 year
Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt on First 180 Days			30.00%				30.00%
Line of Credit Facility, Monthly Percentage of Gross Product Sales Required to be Used as Payment of Debt after the First 180 Days			60.00%				60.00%
Stock Issued During Period, Shares, Commitment Fee (in shares)			323
Stock Issued During Period, Value, Commitment Fee			$ 100,000
Scion Acquisition [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent						$ 771,000			$ 771,000		$ 643,000
Scion Acquisition [Member] | Clyra Medical [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)					21,000
Business Combination, Consideration Transferred, Liabilities Incurred					$ 1,250,000
Business Acquisition, Base Capital Requirement for Escrow Release				$ 1,000,000	$ 1,000,000
Business Acquisition, Gross Revenue, Tranche One				100,000
Business Acquisition, Gross Revenue, Tranche Two				100,000
Business Acquisition, Gross Revenue, Tranche Three				500,000
Business Acquisition, Gross Revenue, Tranche Five				$ 2,000,000
Scion Acquisition [Member] | Clyra Medical [Member] | Clyra Acquisition, Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)				15,500	10,000
Scion Acquisition [Member] | Clyra Medical [Member] | Clyra Acquisition, Common Stock Redeemable for BioLargo Common Shares [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)					7,142,858	3,100
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable						$ 128,000
Scion Solutions [Member] | Clyra Medical [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)									12,400
Debt Instrument, Face Amount					$ 1,250,000
Debt Instrument, Interest Rate, Stated Percentage					5.00%
Debt Instrument, Percent of Investment Proceeds					25.00%
Debt Instrument, Extension Period (Month)					1 year
Debt Instrument, Percent of Gross Revenue					5.00%
Notes Payable, Current, Total						1,007,000			$ 1,007,000
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent						$ 771,000			$ 771,000

Note 8 - Noncontrolling Inter_4

Note 8 - Noncontrolling Interest - Clyra Medical Common and Preferred Shares Outstanding (Details) - Clyra Medical Technology Inc [Member]	Sep. 30, 2020shares
Shares, Outstanding (in shares)	105,629	[1]
Biolargo [Member]
Shares, Outstanding (in shares)	49,207
Percent	47.00%
Sanatio [Member]
Shares, Outstanding (in shares)	18,704
Percent	18.00%
Scion Solutions [Member]
Shares, Outstanding (in shares)	18,600	[2]
Percent	17.00%	[2]
Other [Member]
Shares, Outstanding (in shares)	19,118
Percent	18.00%
[1]	Does not include options to purchase 10,153 of shares of Clyra stock.
[2]	Does not include an additional 12,400 shares held in escrow subject to performance metrics.

Note 9 - BioLargo Engineering_2

Note 9 - BioLargo Engineering, Science and Technologies, LLC (Details Textual) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended		25 Months Ended
	Sep. 30, 2017	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2019	Nov. 04, 2019
Share-based Payment Arrangement, Noncash Expense, Total		$ 1,712	$ 1,201
Percentage of Profits Interests Vested					2.50%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member]
Deferred Compensation Arrangement with Individual, Requisite Service Period (Year)	5 years
Potential Ownership Percentage of Subsidiary Held by Subsidiary Employees Based on Performance	30.00%
Incentive Issuance Stipulations for Subsidiary Employees, Accounts Receivable Collected by Year One of Operation	90.00%
Incentive Issuance Stipulations for Subsidiary Employees, Profit Earned in Year One of Operation	10.00%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	1,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	5 years
Share-based Payment Arrangement, Noncash Expense, Total				$ 0
BioLargo Engineering, Science & Technologies, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Parent	100.00%	97.50%

Note 10 - Business Segment In_3

Note 10 - Business Segment Information (Details Textual)	9 Months Ended
	Sep. 30, 2020
Number of Operating Segments	4

Note 10 - Business Segment In_4

Note 10 - Business Segment Information - Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue		$ 666	$ 534	$ 1,522	$ 1,324
Operating loss		(1,909)	(1,884)	(5,615)	(5,034)
Tangible assets		3,094		3,094		$ 1,728
Investment in South Korean Joint Venture		73		73
Intangible assets		2,021		2,021		1,893
Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture		73		73
Operating Segments [Member] | Odor-No-More [Member]
Revenue		356	396	952	1,012
Operating loss		(144)	(90)	(431)	(231)
Tangible assets		561		561		410
Intangible assets
Operating Segments [Member] | Odor-No-More [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture
Operating Segments [Member] | Clyra Medical [Member]
Tangible assets		1,332		1,332		3
Intangible assets
Operating Segments [Member] | Clyra Medical [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture
Operating Segments [Member] | BLEST [Member]
Tangible assets		282		282		396
Intangible assets
Operating Segments [Member] | BLEST [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture
Operating Segments [Member] | BioLargo Water [Member]
Revenue		21		21
Operating loss		(106)	(136)	(530)	(499)
Tangible assets		93		93		77
Intangible assets
Operating Segments [Member] | BioLargo Water [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture
Operating Segments [Member] | BioLargo Engineering, Science & Technologies, LLC [Member]
Revenue		334	308	778	732
Operating loss		(298)	27	(465)	(110)
Operating Segments [Member] | Clyra Segment [Member]
Revenue		124		145
Operating loss		(491)	(338)	(1,219)	(944)
Corporate, Non-Segment [Member]
Operating loss		(870)	(1,347)	(2,970)	(3,250)
Tangible assets		867		867		862
Intangible assets		2,021		2,021		1,893
Corporate, Non-Segment [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture		73		73
Consolidation, Eliminations [Member]
Tangible assets	[1]	(41)		(41)		(31)
Intangible assets	[1]
Consolidation, Eliminations [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean Joint Venture	[1]
Intersegment Eliminations [Member]
Revenue		$ (169)	$ (170)	$ (374)	$ (420)
[1]	the "elimination" column reflects the net adjustment for receivables and payables generated between our related entities that are eliminated in consolidation.

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating Lease, Expense	$ 167,000	$ 156,000
Lessee, Operating Lease, Renewal Term (Year)	3 years
Lessee, Operating Lease, Discount Rate	18.00%
Lessee, Operating Lease, Liability, to be Paid, Total	$ 578,000
Corporate Office Lease [Member]
Lessee Operating, Lease Annual Escalation Rate	3.00%
Lessee, Operating Lease, Renewal Term (Year)	4 years
Oak Ridge, Tennessee Facility Lease [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual) - USD ($)	Nov. 16, 2020	Jul. 06, 2020	Mar. 30, 2020	Nov. 11, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Proceeds from Issuance of Common Stock									$ 2,380,000
Clyra Medical [Member]
Stock Issued During Period, Shares, New Issues (in shares)									2,742
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member]
Proceeds from Lines of Credit, Total		$ 200,000
Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,785,715		4,893,981	1,398,223	0	6,508,675		0
Proceeds from Issuance of Common Stock			$ 250,000		$ 797,000	$ 295,000		$ 1,043,000	$ 1,700,000
Subsequent Event [Member] | Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member]
Proceeds from Lines of Credit, Total	$ 60,000
Subsequent Event [Member] | Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)				943,667
Proceeds from Issuance of Common Stock				$ 135,000